Zenotech Laboratories Limited (BOM:532039)

Market Cap	2.69B -26.5%
Revenue (ttm)	419.33M +16.5%
Net Income	33.62M -32.6%
EPS	0.55 -32.9%
Shares Out	61.03M
PE Ratio	80.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,345
Average Volume	8,365
Open	43.49
Previous Close	43.04
Day's Range	43.16 - 44.47
52-Week Range	42.05 - 72.87
Beta	-0.17
RSI	43.99
Earnings Date	Apr 27, 2026

About Zenotech Laboratories

Zenotech Laboratories Limited manufactures and markets pharmaceutical specialty generic injectables in the oncology and anesthesiology markets in India. It offers contract manufacturing services for parenteral depot formulations, ophthalmic, oncology oral and injectables, and general injectables. The company also leases out its biotech facility and equipment. In addition, it provides granulocyte-colony stimulating factor and granulocyte-macrophage colony-stimulating factor products. Zenotech Laboratories Limited was incorporated in 1989 and is ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 228
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532039

Financial Performance

In fiscal year 2025, Zenotech Laboratories's revenue was 390.98 million, an increase of 6.22% compared to the previous year's 368.09 million. Earnings were 56.13 million, a decrease of -32.36%.